Jun-06-22 04:30AM |
Editas Medicine Reports Inducement Grants to New Chief Executive OfficerGlobeNewswire Inc. |
Jun-03-22 11:31AM |
Editas (EDIT) Down 20.7% Since Last Earnings Report: Can It Rebound?Zacks Investment Research |
May-18-22 06:45AM |
Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewswire Inc. |
May-13-22 11:52AM |
Why Editas Medicine's Shares Fell 28.9% This WeekThe Motley Fool |
10:32AM |
These 5-Stock Samplers Have Gotten Whacked. And That's OKThe Motley Fool |
May-13-22 10:30AM |
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta ThalassemiaZacks Investment Research |
May-12-22 04:30AM |
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta ThalassemiaGlobeNewswire Inc. |
May-09-22 12:02PM |
Expert Ratings for Editas MedicineBenzinga |
May-04-22 01:30AM |
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology ConferenceGlobeNewswire Inc. |
11:54AM |
Editas' (EDIT) Q1 Loss Narrows, Revenues Beat EstimatesZacks Investment Research |
May-04-22 07:55AM |
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research |
06:45AM |
Editas Medicine Announces First Quarter 2022 Results and Business UpdatesGlobeNewswire Inc. |
Apr-27-22 03:03AM |
Editas Medicine (EDIT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research |
06:55AM |
Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate UpdateGlobeNewswire Inc. |
Apr-19-22 06:20AM |
3 Ominous Reasons to Avoid This Biotech PioneerThe Motley Fool |
Apr-14-22 07:30AM |
Editas Medicine Appoints Gilmore O’Neill as Chief Executive OfficerGlobeNewswire Inc. |
Apr-13-22 10:45AM |
CRISPR Stocks Are Huge -- Here's Why They'll Get Even Bigger by 2030The Motley Fool |
Apr-12-22 11:47AM |
Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug StudyZacks Investment Research |
Mar-21-22 07:44AM |
Editas (EDIT) Soars 6.3%: Is Further Upside Left in the Stock?Zacks Investment Research |
Mar-16-22 12:27PM |
Who Benefits From Amazon's Stock Split?The Motley Fool |
Mar-01-22 07:51AM |
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent ResolutionBenzinga |
Feb-28-22 04:01AM |
Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent InterferenceGlobeNewswire Inc. |
Feb-25-22 11:51AM |
Editas' (EDIT) Q4 Loss Narrows, Revenues Trump EstimatesZacks Investment Research |
11:08AM |
Expert Ratings For Editas MedicineBenzinga |
Feb-24-22 08:01AM |
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine CompanyBenzinga |
07:45AM |
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research |
Feb-24-22 06:30AM |
Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business UpdatesGlobeNewswire Inc. |
Feb-23-22 11:44AM |
Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & MoreZacks Investment Research |
Feb-20-22 08:06AM |
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News FlowBenzinga |
Feb-17-22 03:03AM |
Will Editas Medicine (EDIT) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research |
Feb-16-22 06:15AM |
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate UpdateGlobeNewswire Inc. |
Feb-14-22 12:21PM |
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare DrugZacks Investment Research |
Feb-11-22 12:02PM |
Ultragenyx's (RARE) Q4 Earnings & Revenues Miss EstimatesZacks Investment Research |
Feb-08-22 12:40PM |
Editas Suddenly Terminates Chief Medical Officer Without An ExplanationBenzinga |
08:29AM |
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis BiosimilarBenzinga |
Feb-07-22 01:05AM |
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3Zacks Investment Research |
Feb-02-22 06:40AM |
2 Biotech Stocks That Could Skyrocket This YearThe Motley Fool |
Jan-29-22 10:30AM |
3 Growth ETFs to Consider Buying During This CorrectionThe Motley Fool |
Jan-19-22 10:46AM |
Editas (EDIT) Focuses on Developing Gene-Editing Eye DrugZacks Investment Research |
Jan-13-22 05:24AM |
Why Editas Medicine Stock Is Tumbling This WeekThe Motley Fool |